Cardiff Oncology reports Q4/FY2021 results; mCRC trial shows 34% ORR; Pfizer invests $15M

Cardiff Oncology, Inc.

2021-FY EPS reported -$0.73 revenue$359,000

Onvansertib+FOLFIRI/bevacizumab in KRAS-mutated mCRC: 34% (12/35) ORR at RP2D; mPFS 9.4 months vs ~4.5-5.7 months historical control.
Cash, equivalents, and short-term investments $141M as of Dec 31, 2021; Q4 operating expenses $9.6M (up from $6.6M in 2020).
Pfizer invested $15M via equity purchase of 2.4M shares at $6.22 (19% premium); Pfizer executive to join Scientific Advisory Board.
Appointed Tod Smeal as CSO (ex-Eli Lilly, Pfizer) and Charles Monahan as SVP Regulatory Affairs.
Full year 2021 net cash used in operating activities $23.0M vs $16.3M in 2020.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.